髓过氧化物酶在临床心血管疾病中的意义和研究展望

摘要/Abstract

摘要： 髓过氧化物酶（MPO）是一种含血红素的过氧化物酶,存在于髓系细胞的嗜苯胺蓝颗粒中,是髓细胞的特异性标志。随着研究的深入,发现MPO在心血管疾病的发生发展中,从内皮功能障碍的早期发展到斑块的形成和破裂,MPO氧化应激和炎症反应贯穿了整个过程,MPO催化的反应对潜在的动脉粥样硬化前期有生物活性,MPO催化产生许多反应氧化物及激活物,这些产物能促使脂质过氧化及对靶蛋白产生大量的翻译后修饰作用,包括氯化、硝基化及氧化交联,在动脉粥样硬化及其并发症中发挥重要的作用,与内皮功能障碍、脂质代谢、NO消耗、斑块破裂、MMP的激活、血栓形成都存在广泛的联系。因此,本文对MPO在心血管疾病临床中作用机制和临床意义进行了综述。

李欢, 冯磊, 方绕红, 李海龙, 白梅. 髓过氧化物酶在临床心血管疾病中的意义和研究展望[J]. 心血管病防治知识, 2022, 12(3): 90-94.

参考文献

[1] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要[J].中国循环杂志,2020,35(9):833-854.
[2] Khan AA,Alsahli MA,Rahmani AH.Myeloperoxidase as an Active Disease Biomarker: Recent Biochemical and Pathological Perspectives[J].Med SCI,2018,6(2):33.
[3] Ndrepepa G.Myeloperoxidase-A bridge linking inflammation and oxidative stress with cardiovascular disease[J].Clin Chim Acta,2019,493:36-51.
[4] Naegelen N., Beaume N., Plancon S.,et al.Regulation of neutrophil degranulation and cytokine secretion: A novel model approach based on linear fitting[J].J. Immunol. Res.,2015.
[5] Teng N,Maghzal GJ,Talib J,et al.The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture[J].Redox Rep,2017,22(2):51-73.
[6] Khan, AA,Alsahli MA, Rahmani AH. Myeloperoxidase as an active disease biomarker: Recent biochemical and pathological perspectives[J]. Med Sci. 2018, 6:33.
[7] Malecki C,Hambly BD,Jeremy RW,et al.The Role of Inflflammation and Myeloperoxidase-Related Oxidative Stress in the Pathogenesis of Genetically Triggered Thoracic Aortic Aneurysms[J].Int J Mol Sci,2020,21(20):7678.
[8] Bartesaghi S,Radi R.Fundamentals on the biochemistry of peroxynitrite and protein tyrosine nitration[J]. Redox Biol. 2018, 14: 618-625.
[9] Chaikijurajai T,Tang WHW.Myeloperoxidase: a potential therapeutic target for coronary artery disease[J].Expert Opin Ther Targets,2020,24(7):695-705.
[10] Michos ED, McEvoy JW, Blumenthal RS. Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease[J].New England Journal of Medicine ,2019,381(16):1557-1567.
[11] Huang Y, Wu Z, Riwanto M, et al.Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex[J]. J Clin Invest,2013,123(9):3815-3828.
[12] Narula J, Nakano M, Virmani R, et al.Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques[J]. J Am Coll Cardiol,2013,61(10):1041-1051.
[13] Baldus S,Heeschen C,Meinertz T,et al.Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes[J]. Circulation,2003,108(12):1440-1445.
[14] Brennan ML,Penn MS,Van Lente F,et al.Prognostic value of myeloperoxidase in patients with chest pain[J]. N Engl J Med ,2003,349(17):1595-1604.
[15] Kaya MG,Yalcin R,Okyay K,et al.Potential Role of Plasma Myeloperoxidase Level in Predicting Long-Term Outcome of Acute Myocardial Infarction[J].Tex Heart Inst J,2012,39(4): 500-506.
[16] Sawicki M,Sypniewska G,Kozinski M,et al.Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes[J]. Eur J Clin Invest 2011, 41(6):667-671.
[17] Meuwese MC,Stroes FSG,Hazen SL,et al.Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals[J].J Am Coll Cardiol,2007,50(2):159-165.
[18] Reichlin T, Socrates T, Egli P, et al.Use of myeloperoxidase for risk stratification in acute heart failure[J].?Clin Chem,2010,56:944-951.
[19] Heslop CL,Frohlich JJ,Hill JS.Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography[J].?J Am Coll Cardiol.?2010,55(11):1102-1109.
[20] Li YY,Wang H,Qian J,et al.PRISMA-combined Myeloperoxidase -463G/A gene polymorphism and coronary artery disease[J].Medicine(Baltimore),2017,96(12).